Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amantadine controlled-release - Adamas Pharmaceuticals

Drug Profile

Amantadine controlled-release - Adamas Pharmaceuticals

Alternative Names: ADS-5101; ADS-5102; amantadine ER; amantadine HCl; amantadine HCl extended release; GOCOVRI; Nurelin

Latest Information Update: 26 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase III Movement disorders
  • Discontinued Brain injuries

Most Recent Events

  • 18 Dec 2018 Adamas Pharmaceuticals has patent protection for amantadine controlled-release in USA
  • 05 Oct 2018 Additional efficacy and safety data from a pooled analysis from the phase III EASE LID and EASE LID 3 trials in Drug-induced dyskinesia released by Adamas Pharmaceuticals
  • 02 Aug 2018 Adamas Pharmaceuticals initiates enrolment in an open-label extension phase III trial for Movement disorders in USA (NCT03567057)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top